

RETRACTION NOTE OPEN



Retraction Note: Identification of protein kinase inhibitors to reprogram breast cancer cells

Jie Yuan, Fan Zhang, Meng You and Qin Yang

© The Author(s) 2022

Cell Death and Disease (2022)13:853; https://doi.org/10.1038/s41419-022-05311-9

Retraction to: Cell Death and Disease https://doi.org/10.1038/s41419-018-1002-2, published online 11 September 2018

The Editor-in-Chief has retracted this article. An investigation by the Office of the Vice Chancellor for Research at Washington University in St. Louis concluded that:

- Figure panels 1A, B, and C, labeled as cell line MDA-MB-468, appeared to be falsified and/or fabricated, and were also used in multiple NIH grant applications labeled as breast cancer cell line 4T1 or brain cancer cell line U118.
- Photos in figure panels 2A and 2C, labeled as breast cancer cell line MDA-MB-468, appeared to be falsified, and were also used in multiple NIH grant applications labeled as cell lines 4T1 or BT20.
- Figure panel 2B, labeled as breast cancer cell line MDA-MB-468, appeared to be falsified and/or fabricated, and was also labeled as brain cancer cell line GBM U118 in another publication by the same authors [1].
- Figure 4C, labeled as iFLs from breast cancer cell line MDA-MB-468 in the publication, appeared to be falsified and/or fabricated, and was also used in [1] labeled as iN cells.
- An additional concern identified as part of the investigation is the extensive overlap between this study and another article by the same authors [1].

The authors have not responded to any correspondence from the editor or publisher about this retraction.

REFERENCE

 Yuan J, Zhang F, Hallahan D, Zhang Z, He L, Wu L-W, et al. Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors. J Exp Clin Cancer Res. 2018;37:181. https://doi.org/10.1186/s13046-018-0857-5.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

Published online: 07 October 2022